Markus Warmuth

Markus Warmuth is the Chief Executive Officer of Monte Rosa Therapeutics and a Venture Partner at Versant Ventures, based in Boston, Massachusetts. Prior to his current roles, the serial entrepreneur spent seven years as the CEO of H3 Biomedicine and served as an Entrepreneur-in-Residence at Third Rock Ventures. Earlier in his career, Warmuth held multiple leadership positions at Novartis, including Head of Oncology Drug Discovery and Director of Kinase Biology, where he contributed to the development of the targeted oncology drugs Ceritinib and Ribociclib. He holds an M.D. degree from Ludwig Maximilian University in Munich and currently serves on the board of directors for Ventus Therapeutics. With over 20 years of experience in the biopharmaceutical industry, his primary professional focus remains on advancing precision medicine, oncology treatments, and the development of molecular glue degraders.